Abselion, an innovative company focused on biomolecule quantification technologies, has unveiled its new Protein G Total Antibody Quantification Kit. This kit is specifically developed for use with Abselion's Amperia\u2122 benchtop platform. The introduction of this Protein G-based option complements the existing Protein A format, significantly broadening the range of antibody isotypes and species that researchers can accurately quantify using the platform's intuitive, protocol-guided workflow and sensitive electrochemical detection.
This latest offering from Abselion underscores its ongoing commitment to enhancing the versatility of its Amperia platform. The goal is to provide scientists engaged in various aspects of antibody discovery and development with streamlined tools that support efficient decision-making and optimize bioprocess workflows. The Amperia benchtop platform itself is celebrated for its ease of use, delivering rapid and precise automated quantification of biomolecules without the need for complex optical systems or fluidics.
The Protein G Total Antibody Quantification Kit comes in a ready-to-use format, including Protein G-coated sensor strips, assay plates, detection reagents, and assay buffers. It is suitable for analyzing purified or partially purified antibody samples in both research and process development settings. The assay's mechanism involves sensor strips pre-coated with Protein G, which directly captures antibodies from a sample. After incubation, a labeled detection molecule binds to any remaining unoccupied Fc-binding sites on the sensor. The assay directly measures the electrical signal generated on the sensor tip, which is inversely proportional to the antibody concentration, providing reliable titer data.
In contrast to traditional methods like bio-layer interferometry and surface plasmon resonance, which are often costly and complex, Abselion's Amperia system provides a robust, cost-effective, and automated alternative for accurate antibody titer measurements. With the new Protein G-based option, researchers working with humanized antibodies, rodent IgGs, or engineered variants can now achieve dependable titer measurements without the necessity of revalidating or redesigning their assay setups, thus accelerating their research and development processes.
The launch of this kit signifies Abselion's dedication to meeting the evolving needs of the research community. By expanding the antibody quantification capabilities to include Protein G, Abselion empowers scientists to handle a wider array of antibody formats, fostering greater efficiency and accessibility in practical, application-driven research.
